RaySearch Laboratories AB (publ) publishes preliminary figures for the third quarter of 2022. Order intake increases by 71 percent to SEK 219 (128) million, preliminary net sales increase by 55 percent to SEK 211 (136) million and preliminary EBIT amounts to SEK 12 (-27) million.
RaySearch's interim report for the third quarter will be published on November 29, 2022, at 07:45 am.
Johan Löf, founder and CEO, RaySearch: "It is satisfying to note that the quarter had the highest order intake and net sales ever for a third quarter. It is regrettable that we are moving our reporting date, however I am confident and assured that we have taken the necessary steps to ensure future reporting.”
The main reason for postponing the reporting date is staff turnover in the company's finance function, which has led to delays in the closing process. With regards to staff turnover, this also includes the CFO position. The company had a person in the position for a shorter period from November 2021 to April 2022 and then transitioned into an interim solution where the deputy CEO was acting CFO. As of November 15, as previously communicated, Henrik Bergentoft is the company's permanent CFO.
Analysts, investors, and the media are invited to the presentation of RaySearch's interim report for the third quarter of 2022 on November 29, 2022, at 10:00 am. Johan Löf, founder and CEO, will present the company's development in a webcast. After the presentation (which is held in English), there is an opportunity to ask questions.
Link to webcast: https://raysearchlabs.creo.se/221129
Or dial in to join the webcast:
Sweden: + 46 (0) 8 505 100 31
United Kingdom: +44 (0) 207 107 06 13
United States: +1 (1) 631 570 56 13
This information is information that RaySearch Laboratories AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below, at 10:20 am CET on November 16, 2022.
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch software is used by over 800 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
* Subject to regulatory clearance in some markets.
For more information:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
Henrik Bergentoft, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 73 380 73 69